{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:59:44Z","timestamp":1785387584810,"version":"3.55.0"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Paragangliomas are rare catecholamine-secreting neuroendocrine tumors that can cause significant cardiovascular complications, including catecholamine-induced cardiomyopathy. While surgical resection is the standard of care, some patients are not candidates for surgery or heart transplantation due to tumor biology, genetic risk, or patient preference.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case summary<\/jats:title>\n                    <jats:p>A 68-year-old man with longstanding hypertension, hereditary paraganglioma\u2013pheochromocytoma syndrome (SDHB mutation), and advanced nonischemic cardiomyopathy was evaluated for heart transplantation. Imaging revealed a highly vascular retroperitoneal paraganglioma, and biochemical testing demonstrated markedly elevated chromogranin A with mildly increased plasma free normetanephrine. Biopsy confirmed paraganglioma. Due to transplant ineligibility related to malignancy risk and the patient\u2019s decision to decline surgical resection, medical therapy with lanreotide was initiated. Following treatment, the patient demonstrated biochemical improvement with declining chromogranin A levels, stabilization of blood pressure, improvement in B-type natriuretic peptide, modest recovery of left ventricular ejection fraction, and reduced metabolic activity on serial somatostatin receptor PET\/CT imaging, with stable tumor size. Functional status remained excellent without further heart failure hospitalizations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case highlights lanreotide as a potential non-surgical therapeutic option for paraganglioma-associated cardiomyopathy in select high-risk patients. Systemic tumor control may contribute to cardiovascular stabilization when surgical or transplant options are not feasible.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1861073","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:22:12Z","timestamp":1785385332000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Fluctuating hypertension possibly leading to severe cardiomyopathy in SDHB-associated hereditary paraganglioma: from heart transplant candidacy to long-term lanreotide management: a case report"],"prefix":"10.3389","volume":"13","author":[{"given":"Emily","family":"Pack","sequence":"first","affiliation":[{"name":"West Virginia University School of Medicine","place":["Morgantown, WV, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Sokos","sequence":"additional","affiliation":[{"name":"Department of Cardiology, West Virginia University","place":["Morgantown, WV, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Bianco","sequence":"additional","affiliation":[{"name":"Department of Cardiology, West Virginia University","place":["Morgantown, WV, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Carey","sequence":"additional","affiliation":[{"name":"Department of Cardiology, West Virginia University","place":["Morgantown, WV, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Haider","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, West Virginia University","place":["Morgantown, WV, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Thomay","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, West Virginia University","place":["Morgantown, WV, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiology, West Virginia University","place":["Morgantown, WV, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonikpreet","family":"Aulakh","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, West Virginia University","place":["Morgantown, WV, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"B1","article-title":"Paraganglioma","volume-title":"StatPearls","author":"Ikram","year":"2024"},{"key":"B2","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1186\/s12872-022-03026-5","article-title":"A young patient with heart failure was diagnosed with extra-adrenal paraganglioma: a case report","volume":"22","author":"Zhang","year":"2022","journal-title":"BMC Cardiovasc Disord"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3309","DOI":"10.1016\/j.radcr.2025.03.024","article-title":"Heart failure induced by a tumor in a young adult woman: a case report of dilated cardiomyopathy triggered by paraganglioma","volume":"20","author":"El Abidi","year":"2025","journal-title":"Radiol Case Rep"},{"key":"B4","doi-asserted-by":"publisher","first-page":"4826","DOI":"10.1210\/jc.2008-1093","article-title":"Biochemically silent abdominal paragangliomas in patients with mutations in the succinate dehydrogenase subunit B gene","volume":"93","author":"Timmers","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","first-page":"123456","DOI":"10.3389\/fendo.2023.1204851","article-title":"Pheochromocytoma\/paraganglioma-associated cardiomyopathy","volume":"16","author":"Szatko","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12872-021-02013-6","article-title":"Acute cardiac complications and subclinical myocardial injuries associated with pheochromocytoma and paraganglioma","volume":"21","author":"Zhou","year":"2021","journal-title":"BMC Cardiovasc Disord"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.3390\/jcm9082435","article-title":"Cardiovascular manifestations and complications of pheochromocytomas and paragangliomas","volume":"9","author":"Y-Hassan","year":"2020","journal-title":"J Clin Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1186\/s12872-024-03936-6","article-title":"Hypertension and cardiac damage in pheochromocytoma and paraganglioma patients: a large-scale single-center cohort study","volume":"24","author":"Yu","year":"2024","journal-title":"BMC Cardiovasc Disord"},{"key":"B9","volume-title":"NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors. Version 1.2024","year":"2024"},{"key":"B10","doi-asserted-by":"publisher","first-page":"10612","DOI":"10.1200\/JCO.2025.43.16_suppl.10612","article-title":"A phase 2 study of lanreotide as a therapy for pheochromocytomas (PCs) and paragangliomas (PGs)","volume":"43","author":"Laderian","year":"2025","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"S754","DOI":"10.1016\/j.annonc.2024.08.1210","article-title":"Biochemical and radiological efficacy of systemic lanreotide therapy of patients with advanced, unresectable, non-metastatic paraganglioma\/pheochromocytoma (PPGL), sporadic and hereditary","volume":"35","author":"Kolasi\u0144ska-\u0106wik\u0142a","year":"2024","journal-title":"Ann Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41574-023-00926-0","article-title":"Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert consensus statement","volume":"20","author":"Ta\u00efeb","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1200\/JCO-25-00791","article-title":"Phase II study of 177Lu-DOTATATE for progressive metastatic pheochromocytomas and paragangliomas: interim analysis of efficacy, safety, and biomarkers","volume":"43","author":"Lin","year":"2025","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1136\/heartjnl-2013-304073","article-title":"Acute catecholamine cardiomyopathy in patients with phaeochromocytoma or functional paraganglioma","volume":"99","author":"Giavarini","year":"2013","journal-title":"Heart"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1861073\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:22:13Z","timestamp":1785385333000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1861073\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":14,"alternative-id":["10.3389\/fcvm.2026.1861073"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1861073","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"article-number":"1861073"}}